Published
{
"ticker": "GILD",
"cik": "0000882095",
"company": "Gilead Sciences, Inc.",
"business_type": "pharmaceutical",
"schema_template": "biopharmaceutical: product sales disaggregated by therapeutic franchise, royalty/contract revenue, research and development, acquired in-process research and development, in-process research and development impairments, selling/general/administrative, operating income, net income and per-share amounts; balance sheet centred on cash, marketable securities, intangibles, goodwill and debt; cash flow centred on operating cash flow, capital expenditure, acquisitions, buybacks and dividends",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual dollars (not millions); share counts in actual shares; per-share amounts in dollars",
"units_notes_seen": {
"FY2025 10-K consolidated balance sheets": "(in millions, except per share amounts)",
"FY2025 10-K consolidated statements of operations": "(in millions, except per share amounts)",
"FY2025 10-K consolidated statements of stockholders' equity": "(in millions, except per share amounts)",
"FY2025 10-K consolidated statements of cash flows": "(in millions)",
"FY2025 10-K revenues note, disaggregation of revenues": "(in millions)",
"FY2025 10-K debt and credit facilities note": "(in millions) | Carrying Amount",
"Q2 2026 10-Q condensed consolidated balance sheets": "(in millions, except per share amounts)",
"Q2 2026 10-Q condensed consolidated statements of operations": "(in millions, except per share amounts)",
"Q2 2026 10-Q condensed consolidated statements of stockholders' equity": "(in millions, except per share amounts)",
"Q2 2026 10-Q condensed consolidated statements of cash flows": "(in millions)",
"Q2 2026 10-Q revenues note, disaggregation of revenues": "(in millions)",
"Q2 2026 10-Q debt and credit facilities note": "(in millions) | Carrying Amount"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "none: Gilead reports in U.S. dollars, so no currency translation was applied",
"notes": "Gilead has no stock splits on record over the period covered and its common stock is not an American depositary share, so no per-share restatement was required."
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2025-01-01",
"period_end": "2025-12-31",
"period_type": "fiscal year",
"source_accession": "0000882095-26-000006",
"income_statement": {
"product_sales": 28915000000,
"royalty_contract_and_other_revenues": 527000000,
"total_revenues": 29443000000,
"cost_of_goods_sold": 6234000000,
"gross_profit": 23209000000,
"research_and_development_expenses": 5799000000,
"acquired_in_process_research_and_development_expenses": 1024000000,
"in_process_research_and_development_impairments": 590000000,
"selling_general_and_administrative_expenses": 5774000000,
"total_costs_and_expenses": 19421000000,
"operating_income": 10022000000,
"interest_expense": 1024000000,
"other_income_net": 798000000,
"income_before_income_taxes": 9796000000,
"income_tax_expense": 1286000000,
"net_income": 8510000000,
"net_income_attributable_to_gilead": 8510000000,
"basic_eps": 6.84,
"diluted_eps": 6.78,
"basic_shares": 1244000000,
"diluted_shares": 1255000000
},
"product_sales_by_franchise": {
"biktarvy": 14334000000,
"descovy": 2758000000,
"total_hiv": 20752000000,
"total_liver_disease": 3217000000,
"veklury": 911000000,
"yescarta": 1495000000,
"total_cell_therapy": 1839000000,
"trodelvy": 1397000000,
"total_oncology": 3236000000,
"total_other": 799000000,
"total_product_sales": 28915000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 7564000000,
"short_term_marketable_debt_securities": 68000000,
"accounts_receivable_net": 4913000000,
"inventories": 1774000000,
"prepaid_and_other_current_assets": 4024000000,
"total_current_assets": 18342000000,
"property_plant_and_equipment_net": 5606000000,
"long_term_marketable_debt_securities": 2974000000,
"intangible_assets_net": 16978000000,
"goodwill": 8314000000,
"deferred_tax_assets": 1964000000,
"other_long_term_assets": 4845000000,
"total_assets": 59023000000,
"accounts_payable": 715000000,
"accrued_rebates": 4337000000,
"current_portion_of_long_term_debt": 2807000000,
"other_current_liabilities": 3953000000,
"total_current_liabilities": 11813000000,
"long_term_debt": 22129000000,
"long_term_income_taxes_payable": 896000000,
"deferred_tax_liabilities": 402000000,
"other_long_term_liabilities": 1165000000,
"total_liabilities": 36405000000,
"total_debt": 24937000000,
"additional_paid_in_capital": 8932000000,
"retained_earnings": 13730000000,
"total_gilead_stockholders_equity": 22703000000,
"noncontrolling_interest": -84000000,
"total_stockholders_equity": 22618000000,
"shares_issued_and_outstanding": 1241000000
},
"cash_flow": {
"operating_cash_flow": 10019000000,
"capital_expenditures": -563000000,
"free_cash_flow": 9456000000,
"depreciation_expense": 370000000,
"amortization_expense": 2390000000,
"stock_based_compensation_expense": 894000000,
"acquisitions_including_in_process_research_and_development_net_of_cash_acquired": -1070000000,
"net_cash_used_in_investing_activities": -4793000000,
"proceeds_from_debt_financing": 0,
"repurchases_of_common_stock": -1922000000,
"repayments_of_debt_and_other_obligations": -1788000000,
"dividends_paid": -4003000000,
"net_cash_used_in_financing_activities": -7745000000
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2024-01-01",
"period_end": "2024-12-31",
"period_type": "fiscal year",
"source_accession": "0000882095-26-000006",
"income_statement": {
"product_sales": 28610000000,
"royalty_contract_and_other_revenues": 144000000,
"total_revenues": 28754000000,
"cost_of_goods_sold": 6251000000,
"gross_profit": 22503000000,
"research_and_development_expenses": 5907000000,
"acquired_in_process_research_and_development_expenses": 4663000000,
"in_process_research_and_development_impairments": 4180000000,
"selling_general_and_administrative_expenses": 6091000000,
"total_costs_and_expenses": 27092000000,
"operating_income": 1662000000,
"interest_expense": 977000000,
"other_income_net": 6000000,
"income_before_income_taxes": 690000000,
"income_tax_expense": 211000000,
"net_income": 480000000,
"net_income_attributable_to_gilead": 480000000,
"basic_eps": 0.38,
"diluted_eps": 0.38,
"basic_shares": 1247000000,
"diluted_shares": 1255000000
},
"product_sales_by_franchise": {
"biktarvy": 13423000000,
"descovy": 2113000000,
"total_hiv": 19612000000,
"total_liver_disease": 3021000000,
"veklury": 1799000000,
"yescarta": 1570000000,
"total_cell_therapy": 1973000000,
"trodelvy": 1315000000,
"total_oncology": 3289000000,
"total_other": 889000000,
"total_product_sales": 28610000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 9991000000,
"short_term_marketable_debt_securities": 0,
"accounts_receivable_net": 4420000000,
"inventories": 1710000000,
"prepaid_and_other_current_assets": 3052000000,
"total_current_assets": 19173000000,
"property_plant_and_equipment_net": 5414000000,
"long_term_marketable_debt_securities": 0,
"intangible_assets_net": 19948000000,
"goodwill": 8314000000,
"deferred_tax_assets": 2378000000,
"other_long_term_assets": 3769000000,
"total_assets": 58995000000,
"accounts_payable": 833000000,
"accrued_rebates": 3892000000,
"current_portion_of_long_term_debt": 1815000000,
"other_current_liabilities": 5464000000,
"total_current_liabilities": 12004000000,
"long_term_debt": 24896000000,
"long_term_income_taxes_payable": 830000000,
"deferred_tax_liabilities": 724000000,
"other_long_term_liabilities": 1295000000,
"total_liabilities": 39749000000,
"total_debt": 26710000000,
"additional_paid_in_capital": 7700000000,
"retained_earnings": 11497000000,
"total_gilead_stockholders_equity": 19330000000,
"noncontrolling_interest": -84000000,
"total_stockholders_equity": 19246000000,
"shares_issued_and_outstanding": 1246000000
},
"cash_flow": {
"operating_cash_flow": 10828000000,
"capital_expenditures": -523000000,
"free_cash_flow": 10305000000,
"depreciation_expense": 381000000,
"amortization_expense": 2386000000,
"stock_based_compensation_expense": 835000000,
"acquisitions_including_in_process_research_and_development_net_of_cash_acquired": -4840000000,
"net_cash_used_in_investing_activities": -3449000000,
"proceeds_from_debt_financing": 3464000000,
"repurchases_of_common_stock": -1150000000,
"repayments_of_debt_and_other_obligations": -1970000000,
"dividends_paid": -3918000000,
"net_cash_used_in_financing_activities": -3433000000
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2023-01-01",
"period_end": "2023-12-31",
"period_type": "fiscal year",
"source_accession": "0000882095-26-000006",
"income_statement": {
"product_sales": 26934000000,
"royalty_contract_and_other_revenues": 182000000,
"total_revenues": 27116000000,
"cost_of_goods_sold": 6498000000,
"gross_profit": 20618000000,
"research_and_development_expenses": 5718000000,
"acquired_in_process_research_and_development_expenses": 1155000000,
"in_process_research_and_development_impairments": 50000000,
"selling_general_and_administrative_expenses": 6090000000,
"total_costs_and_expenses": 19511000000,
"operating_income": 7605000000,
"interest_expense": 944000000,
"other_income_net": 198000000,
"income_before_income_taxes": 6859000000,
"income_tax_expense": 1247000000,
"net_income": 5613000000,
"net_income_attributable_to_gilead": 5665000000,
"basic_eps": 4.54,
"diluted_eps": 4.5,
"basic_shares": 1248000000,
"diluted_shares": 1258000000
},
"product_sales_by_franchise": {
"biktarvy": 11850000000,
"descovy": 1985000000,
"total_hiv": 18175000000,
"total_liver_disease": 2784000000,
"veklury": 2184000000,
"yescarta": 1498000000,
"total_cell_therapy": 1869000000,
"trodelvy": 1063000000,
"total_oncology": 2932000000,
"total_other": 859000000,
"total_product_sales": 26934000000
},
"cash_flow": {
"operating_cash_flow": 8006000000,
"capital_expenditures": -585000000,
"free_cash_flow": 7421000000,
"depreciation_expense": 354000000,
"amortization_expense": 2339000000,
"stock_based_compensation_expense": 766000000,
"acquisitions_including_in_process_research_and_development_net_of_cash_acquired": -1152000000,
"net_cash_used_in_investing_activities": -2265000000,
"proceeds_from_debt_financing": 1980000000,
"repurchases_of_common_stock": -1000000000,
"repayments_of_debt_and_other_obligations": -2250000000,
"dividends_paid": -3809000000,
"net_cash_used_in_financing_activities": -5125000000
}
}
],
"quarterly": [
{
"fiscal_year": 2026,
"fiscal_quarter": 2,
"label": "Q2 2026",
"period_start": "2026-04-01",
"period_end": "2026-06-30",
"period_type": "three months",
"source_accession": "0000882095-26-000031",
"income_statement": {
"product_sales": 7627000000,
"royalty_contract_and_other_revenues": 176000000,
"total_revenues": 7803000000,
"cost_of_goods_sold": 1579000000,
"gross_profit": 6224000000,
"research_and_development_expenses": 1764000000,
"acquired_in_process_research_and_development_expenses": 11183000000,
"in_process_research_and_development_impairments": 1750000000,
"selling_general_and_administrative_expenses": 1921000000,
"total_costs_and_expenses": 18197000000,
"operating_income": -10394000000,
"interest_expense": 247000000,
"other_income_net": 387000000,
"income_before_income_taxes": -10254000000,
"income_tax_expense": 242000000,
"net_income": -10496000000,
"net_income_attributable_to_gilead": -10496000000,
"basic_eps": -8.45,
"diluted_eps": -8.45,
"basic_shares": 1243000000,
"diluted_shares": 1243000000
},
"product_sales_by_franchise": {
"biktarvy": 3772000000,
"descovy": 967000000,
"yeztugo": 232000000,
"total_hiv": 5693000000,
"total_liver_disease": 877000000,
"veklury": 23000000,
"yescarta": 346000000,
"total_cell_therapy": 417000000,
"trodelvy": 457000000,
"total_oncology": 873000000,
"total_other": 161000000,
"total_product_sales": 7627000000
},
"balance_sheet": {
"cash_and_cash_equivalents": 3179000000,
"short_term_marketable_debt_securities": 0,
"accounts_receivable_net": 5055000000,
"inventories": 1953000000,
"prepaid_and_other_current_assets": 3759000000,
"total_current_assets": 13945000000,
"property_plant_and_equipment_net": 5833000000,
"long_term_marketable_debt_securities": 0,
"intangible_assets_net": 14032000000,
"goodwill": 8314000000,
"deferred_tax_assets": 2487000000,
"other_long_term_assets": 4751000000,
"total_assets": 49362000000,
"accounts_payable": 674000000,
"accrued_rebates": 4233000000,
"current_portion_of_long_term_debt": 2414000000,
"other_current_liabilities": 3699000000,
"total_current_liabilities": 11020000000,
"long_term_debt": 23832000000,
"long_term_income_taxes_payable": 943000000,
"deferred_tax_liabilities": 333000000,
"other_long_term_liabilities": 1490000000,
"total_liabilities": 37618000000,
"total_debt": 26246000000,
"additional_paid_in_capital": 9532000000,
"retained_earnings": 2200000000,
"total_gilead_stockholders_equity": 11829000000,
"noncontrolling_interest": -84000000,
"total_stockholders_equity": 11744000000,
"shares_issued_and_outstanding": 1241000000
}
},
{
"fiscal_year": 2025,
"fiscal_quarter": 2,
"label": "Q2 2025",
"period_start": "2025-04-01",
"period_end": "2025-06-30",
"period_type": "three months",
"source_accession": "0000882095-26-000031",
"income_statement": {
"product_sales": 7054000000,
"royalty_contract_and_other_revenues": 27000000,
"total_revenues": 7082000000,
"cost_of_goods_sold": 1501000000,
"gross_profit": 5581000000,
"research_and_development_expenses": 1491000000,
"acquired_in_process_research_and_development_expenses": 61000000,
"in_process_research_and_development_impairments": 190000000,
"selling_general_and_administrative_expenses": 1365000000,
"total_costs_and_expenses": 4608000000,
"operating_income": 2474000000,
"interest_expense": 254000000,
"other_income_net": 208000000,
"income_before_income_taxes": 2429000000,
"income_tax_expense": 468000000,
"net_income": 1960000000,
"net_income_attributable_to_gilead": 1960000000,
"basic_eps": 1.57,
"diluted_eps": 1.56,
"basic_shares": 1245000000,
"diluted_shares": 1255000000
},
"product_sales_by_franchise": {
"biktarvy": 3530000000,
"descovy": 653000000,
"yeztugo": 15000000,
"total_hiv": 5088000000,
"total_liver_disease": 795000000,
"veklury": 121000000,
"yescarta": 393000000,
"total_cell_therapy": 485000000,
"trodelvy": 364000000,
"total_oncology": 849000000,
"total_other": 202000000,
"total_product_sales": 7054000000
}
}
],
"notes": [
"Annual figures for 2025, 2024 and 2023 come from Gilead's FY2025 Form 10-K (accession 0000882095-26-000006). The second-quarter and six-month figures come from the Form 10-Q for the quarter ended June 30, 2026 (accession 0000882095-26-000031).",
"The 10-K presents three years on the statements of operations and cash flows but only two balance sheets, as of December 31, 2025 and 2024. FY2023 therefore carries an income statement and a cash flow statement here, and no balance sheet.",
"The 10-Q presents cash flows for the six months only, not for the three-month quarter. The quarterly entries therefore carry no cash flow statement; the six-month cash flows, with their prior-year comparative, are in the year-to-date block.",
"Neither filing presents the first quarter of 2026 on its face, so this record contains no first-quarter 2026 entry.",
"Gilead's income statement line is captioned 'Other (income) expense, net'. It is carried here as other_income_net, stated so that a positive figure is net other income that adds to pre-tax income and a negative figure is a net expense. The six months ended June 30, 2025 is the one period in this record where that line was a net expense.",
"Gilead does not print a gross profit subtotal. The gross_profit line here is total revenues less cost of goods sold.",
"Gilead does not print a total liabilities subtotal. The total_liabilities line here is total assets less total stockholders' equity, and it agrees with the sum of the individual liability captions the balance sheet does print.",
"free_cash_flow is operating cash flow less purchases of property, plant and equipment, both as reported in the statement of cash flows.",
"total_debt is the 'Total debt, net' subtotal from the debt and credit facilities note: $26,246 million at June 30, 2026, $24,937 million at December 31, 2025 and $26,710 million at December 31, 2024.",
"The trailing-twelve-month block is derived line by line as fiscal year 2025 plus the six months ended June 30, 2026 less the six months ended June 30, 2025. It carries no per-share amounts, because weighted-average share counts cannot be added across periods.",
"The second quarter of 2026 carries $11,183 million of acquired in-process research and development expense, arising from the completed acquisitions of Arcellx, Inc., Tubulis GmbH and Ouro Medicines, LLC, together with $1,750 million of in-process research and development impairments. Those charges are what turned an otherwise growing revenue base into a $10,496 million net loss for the quarter and a $8,475 million net loss for the six months.",
"In loss-making periods the diluted share count equals the basic count, because potential shares would be anti-dilutive. That is why the Q2 2026 and six-month 2026 basic and diluted losses per share are identical at $8.45 and $6.82.",
"For the quarterly and six-month periods, net income attributable to Gilead equals consolidated net income: the statements of stockholders' equity allocate none of those periods' results to the noncontrolling interest. The two differ only in 2023, when a $52 million net loss was attributable to the noncontrolling interest.",
"Yeztugo is shown as a separate product line in the 2026 quarterly and six-month revenue disaggregation but not in the FY2025 10-K, which includes it within Other HIV. The annual periods therefore carry no separate Yeztugo line.",
"Gilead states in its filings that \"certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding,\" and its printed subtotals do differ from the sum of their own components by $1 million in a number of places. Examples: FY2025 total revenues are printed as $29,443 million against components of $29,442 million; FY2025 total stockholders' equity is printed as $22,618 million against $22,619 million from the Gilead and noncontrolling-interest lines; FY2024 income before income taxes is printed as $690 million against $691 million from the lines above it; FY2023 net income is printed as $5,613 million against $5,612 million from pre-tax income less tax; second-quarter 2025 product sales are printed as $7,054 million against franchise lines summing to $7,055 million. Every figure in this record is the figure the filing printed on that line, not a recomputed one, so these differences are preserved rather than smoothed away. The derived trailing-twelve-month subtotals inherit them."
],
"uncertainties": [
"Two derived trailing-twelve-month subtotals sit $1 million away from the sum of their own components, inherited from the rounding in the six months ended June 30, 2025 column: total costs and expenses of $32,954 million against components summing to $32,953 million, and a loss before income taxes of $1,955 million against $1,956 million from the lines above it. The trailing-twelve-month franchise lines likewise sum to $29,822 million against total product sales of $29,821 million.",
"Total debt is taken from the debt note's 'Total debt, net' line. At December 31, 2025 that note reads $24,937 million while the balance sheet's current and long-term debt captions sum to $24,936 million; at December 31, 2024 the note reads $26,710 million against $26,711 million from the balance sheet. These are rounding differences within the filing, and the note's subtotal was used.",
"No balance sheet as of June 30, 2025 is presented in either filing, so the year-ago quarter carries an income statement and product sales only.",
"Gilead's cost of goods sold is reported as a single line and the filings do not separate the amortization of acquired product intangibles within it, so the gross_profit figure here should be read as a gross margin after that amortization rather than a cash production cost."
],
"year_to_date": {
"label": "Six months ended June 30, 2026",
"period_start": "2026-01-01",
"period_end": "2026-06-30",
"period_type": "six months",
"source_accession": "0000882095-26-000031",
"income_statement": {
"product_sales": 14574000000,
"royalty_contract_and_other_revenues": 189000000,
"total_revenues": 14763000000,
"cost_of_goods_sold": 3023000000,
"gross_profit": 11740000000,
"research_and_development_expenses": 3136000000,
"acquired_in_process_research_and_development_expenses": 11290000000,
"in_process_research_and_development_impairments": 1750000000,
"selling_general_and_administrative_expenses": 3372000000,
"total_costs_and_expenses": 22571000000,
"operating_income": -7808000000,
"interest_expense": 487000000,
"other_income_net": 621000000,
"income_before_income_taxes": -7674000000,
"income_tax_expense": 801000000,
"net_income": -8475000000,
"net_income_attributable_to_gilead": -8475000000,
"basic_eps": -6.82,
"diluted_eps": -6.82,
"basic_shares": 1243000000,
"diluted_shares": 1243000000
},
"product_sales_by_franchise": {
"biktarvy": 7133000000,
"descovy": 1774000000,
"yeztugo": 397000000,
"total_hiv": 10723000000,
"total_liver_disease": 1644000000,
"veklury": 167000000,
"yescarta": 679000000,
"total_cell_therapy": 824000000,
"trodelvy": 859000000,
"total_oncology": 1683000000,
"total_other": 357000000,
"total_product_sales": 14574000000
},
"cash_flow": {
"operating_cash_flow": 6117000000,
"capital_expenditures": -257000000,
"free_cash_flow": 5860000000,
"depreciation_expense": 191000000,
"amortization_expense": 1196000000,
"stock_based_compensation_expense": 449000000,
"acquisitions_including_in_process_research_and_development_net_of_cash_acquired": -11318000000,
"net_cash_used_in_investing_activities": -8577000000,
"proceeds_from_debt_financing": 4085000000,
"repurchases_of_common_stock": -774000000,
"repayments_of_debt_and_other_obligations": -2783000000,
"dividends_paid": -2069000000,
"net_cash_used_in_financing_activities": -1895000000
},
"prior_year_comparative": {
"label": "Six months ended June 30, 2025",
"period_start": "2025-01-01",
"period_end": "2025-06-30",
"period_type": "six months",
"source_accession": "0000882095-26-000031",
"income_statement": {
"product_sales": 13668000000,
"royalty_contract_and_other_revenues": 81000000,
"total_revenues": 13749000000,
"cost_of_goods_sold": 3041000000,
"gross_profit": 10708000000,
"research_and_development_expenses": 2870000000,
"acquired_in_process_research_and_development_expenses": 315000000,
"in_process_research_and_development_impairments": 190000000,
"selling_general_and_administrative_expenses": 2623000000,
"total_costs_and_expenses": 9038000000,
"operating_income": 4711000000,
"interest_expense": 513000000,
"other_income_net": -120000000,
"income_before_income_taxes": 4077000000,
"income_tax_expense": 802000000,
"net_income": 3275000000,
"net_income_attributable_to_gilead": 3275000000,
"basic_eps": 2.63,
"diluted_eps": 2.61,
"basic_shares": 1246000000,
"diluted_shares": 1257000000
},
"product_sales_by_franchise": {
"biktarvy": 6679000000,
"descovy": 1239000000,
"yeztugo": 15000000,
"total_hiv": 9675000000,
"total_liver_disease": 1553000000,
"veklury": 423000000,
"yescarta": 779000000,
"total_cell_therapy": 949000000,
"trodelvy": 657000000,
"total_oncology": 1606000000,
"total_other": 410000000,
"total_product_sales": 13668000000
},
"cash_flow": {
"operating_cash_flow": 2584000000,
"capital_expenditures": -211000000,
"free_cash_flow": 2373000000,
"depreciation_expense": 190000000,
"amortization_expense": 1197000000,
"stock_based_compensation_expense": 434000000,
"acquisitions_including_in_process_research_and_development_net_of_cash_acquired": -294000000,
"net_cash_used_in_investing_activities": -2531000000,
"proceeds_from_debt_financing": 0,
"repurchases_of_common_stock": -1257000000,
"repayments_of_debt_and_other_obligations": -1771000000,
"dividends_paid": -2004000000,
"net_cash_used_in_financing_activities": -4993000000
}
}
},
"trailing_twelve_months": {
"label": "Trailing twelve months ended June 30, 2026",
"period_start": "2025-07-01",
"period_end": "2026-06-30",
"period_type": "trailing twelve months",
"source_accessions": [
"0000882095-26-000006",
"0000882095-26-000031"
],
"derivation": "fiscal year 2025 plus the six months ended June 30, 2026 less the six months ended June 30, 2025, line by line",
"income_statement": {
"product_sales": 29821000000,
"royalty_contract_and_other_revenues": 635000000,
"total_revenues": 30457000000,
"cost_of_goods_sold": 6216000000,
"gross_profit": 24241000000,
"research_and_development_expenses": 6065000000,
"acquired_in_process_research_and_development_expenses": 11999000000,
"in_process_research_and_development_impairments": 2150000000,
"selling_general_and_administrative_expenses": 6523000000,
"total_costs_and_expenses": 32954000000,
"operating_income": -2497000000,
"interest_expense": 998000000,
"other_income_net": 1539000000,
"income_before_income_taxes": -1955000000,
"income_tax_expense": 1285000000,
"net_income": -3240000000,
"net_income_attributable_to_gilead": -3240000000
},
"product_sales_by_franchise": {
"biktarvy": 14788000000,
"descovy": 3293000000,
"total_hiv": 21800000000,
"total_liver_disease": 3308000000,
"veklury": 655000000,
"yescarta": 1395000000,
"total_cell_therapy": 1714000000,
"trodelvy": 1599000000,
"total_oncology": 3313000000,
"total_other": 746000000,
"total_product_sales": 29821000000
},
"cash_flow": {
"operating_cash_flow": 13552000000,
"capital_expenditures": -609000000,
"free_cash_flow": 12943000000,
"depreciation_expense": 371000000,
"amortization_expense": 2389000000,
"stock_based_compensation_expense": 909000000,
"acquisitions_including_in_process_research_and_development_net_of_cash_acquired": -12094000000,
"net_cash_used_in_investing_activities": -10839000000,
"proceeds_from_debt_financing": 4085000000,
"repurchases_of_common_stock": -1439000000,
"repayments_of_debt_and_other_obligations": -2800000000,
"dividends_paid": -4068000000,
"net_cash_used_in_financing_activities": -4647000000
}
},
"headline": {
"period": "Q2 FY2026",
"period_end_words": "June 30, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 7803000000,
"text": "$7.80 billion",
"exact": "$7,803,000,000",
"compact": "$7.80B",
"abs": "$7.80 billion",
"prior_value": 7082000000,
"prior": "$7.08 billion",
"priorabs": "$7.08 billion",
"yoy": "up 10.2%",
"source": {
"array": "quarterly",
"field": "income_statement.total_revenues",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000882095-26-000031",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": -10496000000,
"text": "-$10.50 billion",
"exact": "-$10,496,000,000",
"compact": "-$10.50B",
"abs": "$10.50 billion",
"prior_value": 1960000000,
"prior": "$1.96 billion",
"priorabs": "$1.96 billion",
"yoy": "swung from $1.96 billion",
"source": {
"array": "quarterly",
"field": "income_statement.net_income_attributable_to_gilead",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000882095-26-000031",
"gap_days": 365
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": -8.45,
"text": "-$8.45",
"exact": "-$8.45",
"compact": "-$8.45",
"abs": "$8.45",
"prior_value": 1.56,
"prior": "$1.56",
"priorabs": "$1.56",
"yoy": "swung from $1.56",
"source": {
"array": "quarterly",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000882095-26-000031",
"gap_days": 365
}
},
{
"label": "Product sales",
"format": "usd",
"value": 7627000000,
"text": "$7.63 billion",
"exact": "$7,627,000,000",
"compact": "$7.63B",
"abs": "$7.63 billion",
"prior_value": 7054000000,
"prior": "$7.05 billion",
"priorabs": "$7.05 billion",
"yoy": "up 8.1%",
"source": {
"array": "quarterly",
"field": "income_statement.product_sales",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000882095-26-000031",
"gap_days": 365
}
},
{
"label": "HIV product sales",
"format": "usd",
"value": 5693000000,
"text": "$5.69 billion",
"exact": "$5,693,000,000",
"compact": "$5.69B",
"abs": "$5.69 billion",
"prior_value": 5088000000,
"prior": "$5.09 billion",
"priorabs": "$5.09 billion",
"yoy": "up 11.9%",
"source": {
"array": "quarterly",
"field": "product_sales_by_franchise.total_hiv",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0000882095-26-000031",
"gap_days": 365
}
},
{
"label": "Acquired IPR&D charges",
"format": "usd",
"value": 11183000000,
"text": "$11.18 billion",
"exact": "$11,183,000,000",
"compact": "$11.18B",
"abs": "$11.18 billion",
"prior_value": null,
"prior": null,
"priorabs": null,
"yoy": null,
"source": {
"array": "quarterly",
"field": "income_statement.acquired_in_process_research_and_development_expenses",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031"
}
},
{
"label": "IPR&D impairment",
"format": "usd",
"value": 1750000000,
"text": "$1.75 billion",
"exact": "$1,750,000,000",
"compact": "$1.75B",
"abs": "$1.75 billion",
"prior_value": null,
"prior": null,
"priorabs": null,
"yoy": null,
"source": {
"array": "quarterly",
"field": "income_statement.in_process_research_and_development_impairments",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0000882095-26-000031"
}
}
],
"summary": "Gilead Sciences reported $7.80 billion in total revenues for Q2 FY2026, the quarter ended June 30, 2026, up 10.2% from a year earlier, with product sales of $7.63 billion, up 8.1%, but posted a net loss of $10.50 billion, or $8.45 per diluted share. The loss was driven mainly by $11.18 billion of acquired in-process research and development charges on three acquisitions that closed during the quarter, expensed at once rather than capitalized, and by a further $1.75 billion impairment that wrote a lung cancer intangible to zero. Underneath those charges the commercial business grew, led by HIV, where product sales were $5.69 billion, up 11.9%.",
"qa": [
{
"q": "Did Gilead lose money in Q2 FY2026?",
"a": "Yes. Gilead Sciences posted a net loss of $10.50 billion for Q2 FY2026, the quarter ended June 30, 2026, and a diluted loss per share of $8.45, against net income of $1.96 billion and diluted earnings per share of $1.56 in the same quarter a year earlier."
},
{
"q": "Why did Gilead report a loss in Q2 FY2026?",
"a": "Gilead Sciences recorded $11.18 billion of acquired in-process research and development charges in Q2 FY2026 on three acquisitions that closed during the quarter. Those charges are expensed immediately rather than carried on the balance sheet, and together with an in-process research and development impairment on a discontinued lung cancer program they are the main reason the quarter ended in a net loss of $10.50 billion even as revenue rose."
},
{
"q": "How much revenue did Gilead report in Q2 FY2026?",
"a": "Gilead Sciences reported $7.80 billion in total revenues for Q2 FY2026, the quarter ended June 30, 2026. That is up 10.2% from $7.08 billion in the same quarter a year earlier, and product sales were $7.63 billion, up 8.1%, with the rest of the increase coming from previously constrained revenue recognized on a sale of intellectual property."
},
{
"q": "How big is Gilead's HIV business?",
"a": "HIV medicines remain the core of Gilead Sciences, with product sales of $5.69 billion in Q2 FY2026, up 11.9% from $5.09 billion a year earlier. That is the largest of the company's therapeutic franchises and the bulk of its total revenues of $7.80 billion."
}
]
},
"company_details": {
"Name": "Gilead Sciences, Inc.",
"Ticker": "GILD",
"CIK": "0000882095",
"Exchange": "Nasdaq",
"State": "California",
"Incorporation": "Delaware",
"SIC": "2836",
"Office": "Life Sciences",
"Industry": "Biological Products, (No Diagnostic Substances)"
},
"next_filing": {
"predicted_date": "2026-11-03",
"predicted_type": "10-Q"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"form": "10-Q",
"accession": "0000882095-26-000031",
"fiscal_year_end": "1231",
"source": "facts"
}
}